Thermo Fisher Scientific, a prominent figure in the scientific community, is utilising an advanced platform technology along with a new CHO K-1 cell line that can shorten the timeline for Investigational New Drug (IND) filing from 13 to nine months. This innovation aids biotech and pharmaceutical companies in navigating the logistical challenges associated with pre-clinical biologic drug development.
Thermo Fisher’s comprehensive offerings enable clients to embark on their journey immediately upon the selection of a candidate. Our approach of “start here, stay here” guarantees that we are equipped to meet customer needs throughout every phase of the clinical development journey, adapting alongside them as they advance. Thermo Fisher enables biotech and pharma companies to streamline their procurement strategy by reducing reliance on multiple vendors, ultimately leading to significant savings in both time and money.
“By prioritizing speed to market and simplification of complex processes, Thermo Fisher is enabling a new era of biologics drug development,” said Jennifer Cannon, president of commercial operations, pharma services at Thermo Fisher Scientific. “Small to large-sized biotech companies, as well as pharmaceutical organizations, require faster and more seamless Biologics cell line development capabilities and support. As such, we have developed an end-to-end Gene to Patient integrated solution to accelerate the delivery of life-saving therapies. We are excited to offer these expanded solutions that meet this need.”
By utilising Accelerator Drug Development, Thermo Fisher offers a comprehensive suite of services through its Contract Development and Manufacturing Organisation (CDMO), Contract Research Organisation (CRO), and bioprocessing solutions. Clients can tap into the extensive range of the company’s integrated offerings, which include tailored manufacturing capabilities, clinical research, supply chain services, and bioprocessing capacity. The CHO K-1 cell line presents enhanced efficiency and optimisation towards achieving IND status. This thorough strategy guarantees a dependable supply chain, providing steady assistance from the initial pre-clinical phases all the way to commercial biologcs drug development.
